Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | ATP4A | P20648 | 1/20 | 0.34 |
| ▸ | ATP4B | P51164 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790530 | 0.84 | LIPG (0.50) | GABRA1GABRB2LIPGLPLELANE | |
| SCHEMBL3787657 | 0.83 | LIPG (0.40) | GABRA1GABRB2LIPGALDH1A1KDM4E | |
| SCHEMBL3786328 | 0.81 | LIPG (0.61) | LIPGLPLELANE | |
| SCHEMBL1332031 | 0.79 | GABRA1 (0.55) | GABRA1GABRB2ALDH1A1KDM4EELANE | |
| SCHEMBL262868 | 0.79 | GABRA1 (0.55) | GABRA1GABRB2ALDH1A1KDM4EELANE | |
| SCHEMBL29468961 | 0.78 | LIPG (0.61) | GABRA1GABRB2LIPGALDH1A1LPL | |
| SCHEMBL410387 | 0.78 | LIPG (0.61) | GABRA1GABRB2LIPGALDH1A1LPL | |
| SCHEMBL28967677 | 0.77 | GABRA1 (0.52) | GABRA1GABRB2ALDH1A1KDM4EELANE | |
| SCHEMBL30319989 | 0.77 | GABRA1 (0.52) | GABRA1GABRB2ALDH1A1KDM4EELANE | |
| Hydrochloric Acid SCHEMBL625383 | 0.77 | GABRA1 (0.52) | GABRA1GABRB2ALDH1A1KDM4EELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | GABRA1 991/4885GABRB2 561/4885LIPG 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.